<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779697</url>
  </required_header>
  <id_info>
    <org_study_id>2000027868</org_study_id>
    <secondary_id>2R01DK099039-06</secondary_id>
    <nct_id>NCT04779697</nct_id>
  </id_info>
  <brief_title>GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight</brief_title>
  <official_title>GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with&#xD;
      obesity and assess impact on craving, hunger, stress, and weight outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled 12-week study with GLP-1 analogue&#xD;
      (semaglutide) in men and women with obesity (BMI 30-49.9 kg/m2) in a validated laboratory&#xD;
      model to identifying processes underlying greater food craving, intake and weight change, in&#xD;
      order to test mechanisms by which a GLP-1 analogues may exerts significant weight effects in&#xD;
      obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Craving</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Craving will be measured using a validated questionnaire called Food Craving Scale (FCS). FCS is an 28-item questionnaire that measures how often participates experienced a craving for a food type. Participants can respond to each item from &quot;never&quot; to &quot;always/ almost every&quot;. HIgher scores indicate greater craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hunger</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Hunger will be measured in a Visual Analog Scale (VAS) range from 0 to 9. Higher VAS indicates greater hunger.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Food Intake</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Food intake will be measured in KCalories during a validated observed laboratory task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>weekly for 12 weeks</time_frame>
    <description>Weight in kilograms will be assessed using a bioimpedance scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in food intake - real-life</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
    <description>Food intake will be measured in Kcalories using 3-day 24hr recall (ASA24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
    <description>Stress, measured as total score on the 14-item Perceived Stress Scale, with higher scores indicating greater subjective stress.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>GLP-1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pen administered weekly over 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 analogue - semaglutide</intervention_name>
    <description>GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks</description>
    <arm_group_label>GLP-1a</arm_group_label>
    <other_name>Semaglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - administered once weekly for a total of 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI ranging from 30-49.9 kg/m2&#xD;
&#xD;
          -  No significant medical problems, including diabetes&#xD;
&#xD;
          -  No history of HgbA1c &lt;6.5%&#xD;
&#xD;
          -  English speaking and able to read English and complete study evaluations&#xD;
&#xD;
          -  Able to provide informed written and verbal consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant current medical conditions, including neurological, renal, thyroid,&#xD;
             cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or&#xD;
             T1DM by American Diabetes Association (ADA) criteria&#xD;
&#xD;
          -  Meet current or past DSM-IVR criteria for alcohol dependence or any substance use&#xD;
             disorders, including nicotine, or psychiatric disorders, including eating disorders,&#xD;
             or use of any psychiatric medications, including anxiolytics, antidepressants,&#xD;
             naltrexone or antabuse, anti-smoking medications&#xD;
&#xD;
          -  Current active participation in a weight loss program or weight loss of &gt;10% of total&#xD;
             body weight during the prior 6 months&#xD;
&#xD;
          -  Taking any other anti-obesity medication&#xD;
&#xD;
          -  History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who&#xD;
             are pregnant or lactating, or peri/postmenopausal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ania Jastreboff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology);</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajita Sinha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatry; Director Yale Stress Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ania Jastreboff, MD, PhD</last_name>
    <phone>(203) 737-5015</phone>
    <email>ania.jastreboff@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajita Sinha, PhD</last_name>
    <phone>(203) 737-1272</phone>
    <email>rajita.sinha@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Yale Stress Center: Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seungju Hwang, BS</last_name>
      <phone>203-737-4011</phone>
      <email>seungju.hwang@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ania Jastreboff, MD, PHD</last_name>
      <email>ania.jastreboff@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ania Jastreboff, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

